$50M milestone payment goes to Pharmacyclics for blood cancer drug

11/21/2013 | American City Business Journals

Pharmacyclics has earned a $50 million milestone payment from partner Johnson & Johnson after the European Medicines Agency accepted an application for the review of Imbruvica. Last week, the company earned a $60 million milestone fee from J&J subsidiary Janssen Biotech when the FDA approved Imbruvica for the treatment of mantle cell lymphoma.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR